A comprehensive study shows that people with fatty liver disease have almost twice the mortality rate of the general population. They have an increased risk of dying from both liver diseases and ...

Despite this, there are no polymeric NPs that are approved for treatment of liver diseases. This is surprising since─when administered intravenously─the majority of NPs accumulate in cells in the ...